Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Pain
- Disease
- Migraine
- Therapeutic
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 390159
The patents and patent applications disclose novel compounds, pharmaceutical compositions and methods of treating various diseases including those other than migraine such as pain, hot flashes, cluster headache and other CGRP-mediated cerebrovascular and vascular disorders. The patents and patent applications include, for example, U.S. Patents 9,808,457 and 10,300,056.
U.S. Patent 9,808,457 – CGRP receptor antagonists
U.S. Patent 10,300,056 – CGRP receptor antagonists
Calcitonin gene related peptide (CGRP) receptor antagonism, glutamate modulation, myeloperoxidase ('MPO') inhibition, Kv7 Ion Channel Activators (Kv7), and Myostatin.
CGRP stands for calcitonin gene-related peptide, and it is a protein that is released around the brain. When CGRP is released, it causes intense inflammation in the coverings of the brain (the meninges), and for most migraine patients, causes the pain of a migraine attack.
Licensee is a biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.
IPSCIO Record ID: 220108
The Agreement resolves the Licensees appeal following opposition proceedings before the European Patent Office related to the Licensors European Patent No. 1957106 B1, with respect to calcitonin gene-related peptide antagonist antibodies.
IPSCIO Record ID: 279382
The patents include, but are not limited to Excitatory amino acid receptor antagonists, and, Process for preparing isoquinoline compounds, and, Synthesis of cis-decahydroisoquinoline-3-carboxylic acids.
AMPA/kainate, or AK, antagonist assets including its lead drug candidate, tezampanel, and NGX426.
Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research. It suppresses both the withdrawal symptoms from morphine and other opioids, and the development of tolerance,as well as having and analgesic effects in its own right. It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.
IPSCIO Record ID: 324861
Assets to be Purchased All patents, patents pending, trademarks, research and development materials, raw materials, (including compounds in storage), chemical entities in the patent estate namely AND-302; AND-378; AND-383; AND-380; and AND-407, also referenced in and by the following (the “Intellectual Propertyâ€) (a.) PCT WO2012/074784 A2 – “Novel Fluorinated Sulfamides Exhibiting Neuroprotective Action and Their Method of Useâ€; (b.) US Patent 8,609,849 – “Novel Hydroxylated Sulfamides Exhibiting Neuroprotective Action and Their Method of Useâ€; (c.) All compounds contained in an original provisional patent relating to piperidine chemistry for refractory epilepsy, namely AND-378 and AND-383; and (d.) All technology described in the Phase 2 SBIR Research Strategy pertaining to the aforementioned body of intellectual property and technology (the Intellectual Property or IP).
8,609,849 – Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
“Field†means the human use of the Manufactured Products in pharmaceutical preparations, including but not limited to per os (oral tablets or capsules), intravenous, topical skin, intranasal cavaties, anal suppositories, or subcutaneous implants.
The field of use is for the treatment of neurological disorders.
Neurological disorders are diseases of the central and peripheral nervous system. These disorders include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinsons disease, neuroinfections, brain tumours, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.
